280 related articles for article (PubMed ID: 28697319)
1. Renal Medullary Carcinoma: Establishing Standards in Practice.
Beckermann KE; Sharma D; Chaturvedi S; Msaouel P; Abboud MR; Allory Y; Bourdeaut F; Calderaro J; de Cubas AA; Derebail VK; Hong AL; Naik RP; Malouf GG; Mullen EA; Reuter VE; Roberts CWM; Walker CL; Wood CG; DeBaun MR; Van Poppel H; Tannir NM; Rathmell WK
J Oncol Pract; 2017 Jul; 13(7):414-421. PubMed ID: 28697319
[TBL] [Abstract][Full Text] [Related]
2. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.
Msaouel P; Hong AL; Mullen EA; Atkins MB; Walker CL; Lee CH; Carden MA; Genovese G; Linehan WM; Rao P; Merino MJ; Grodman H; Dome JS; Fernandez CV; Geller JI; Apolo AB; Daw NC; Hodges HC; Moxey-Mims M; Wei D; Bottaro DP; Staehler M; Karam JA; Rathmell WK; Tannir NM
Clin Genitourin Cancer; 2019 Feb; 17(1):1-6. PubMed ID: 30287223
[TBL] [Abstract][Full Text] [Related]
3. Renal Medullary Carcinoma: a Report of the Current Literature.
Blas L; Roberti J; Petroni J; Reniero L; Cicora F
Curr Urol Rep; 2019 Jan; 20(1):4. PubMed ID: 30656488
[TBL] [Abstract][Full Text] [Related]
4. Is renal medullary carcinoma the seventh nephropathy in sickle cell disease? A multi-center Nigerian survey.
Anazoeze M; Najibah G; Garba U; Shehu A; Florence F; Abdulaziz H; Marcus I; Oluwaseun A; Theresa N; Obike I; Sunday O; Ifeoma E; Anthony I; Barth C; Chide O; Joseph O; Malachy I; Kaladada K; Uche A; Kingsley A; Charles N; Angela U; Augustin D; Chikwudi A; Alozie E; Uchenna O; Caroline O; Obineche A; Iheanyi O
Afr Health Sci; 2016 Jun; 16(2):490-6. PubMed ID: 27605964
[TBL] [Abstract][Full Text] [Related]
5. Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy.
Schaeffer EM; Guzzo TJ; Furge KA; Netto G; Westphal M; Dykema K; Yang X; Zhou M; Teh BT; Pavlovich CP
BJU Int; 2010 Jul; 106(1):62-5. PubMed ID: 20002663
[TBL] [Abstract][Full Text] [Related]
6. Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma.
Beckermann KE; Jolly PC; Kim JY; Bordeaux J; Puzanov I; Rathmell WK; Johnson DB
J Immunother Cancer; 2017; 5():1. PubMed ID: 28105368
[TBL] [Abstract][Full Text] [Related]
7. A Model Linking Sickle Cell Hemoglobinopathies and SMARCB1 Loss in Renal Medullary Carcinoma.
Msaouel P; Tannir NM; Walker CL
Clin Cancer Res; 2018 May; 24(9):2044-2049. PubMed ID: 29440190
[TBL] [Abstract][Full Text] [Related]
8. Renal cell carcinoma, unclassified with medullary phenotype: poorly differentiated adenocarcinomas overlapping with renal medullary carcinoma.
Sirohi D; Smith SC; Ohe C; Colombo P; Divatia M; Dragoescu E; Rao P; Hirsch MS; Chen YB; Mehra R; Amin MB
Hum Pathol; 2017 Sep; 67():134-145. PubMed ID: 28716439
[TBL] [Abstract][Full Text] [Related]
9. Renal Medullary Carcinoma: A Surveillance, Epidemiology, and End Results (SEER) Analysis.
Haupt T; Akinyemi O; Raju RA; Wadley AE; Nnorom S; Aponte V; Thelus J; Tonkin JB; Coleman PW; Metwalli AR
J Surg Res; 2023 Dec; 292():1-6. PubMed ID: 37567029
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances in Renal Medullary Carcinoma.
Su Y; Hong AL
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806102
[TBL] [Abstract][Full Text] [Related]
11. SMARCB1/INI1 inactivation in renal medullary carcinoma.
Calderaro J; Moroch J; Pierron G; Pedeutour F; Grison C; Maillé P; Soyeux P; de la Taille A; Couturier J; Vieillefond A; Rousselet MC; Delattre O; Allory Y
Histopathology; 2012 Sep; 61(3):428-35. PubMed ID: 22686875
[TBL] [Abstract][Full Text] [Related]
12. Renal Medullary Carcinoma and Sickle Cell Trait: A Push for Early Diagnosis and Intervention Report of Two Cases.
Carter SA; Walker AN
J Natl Med Assoc; 2017 Spring; 109(1):63-65. PubMed ID: 28259220
[TBL] [Abstract][Full Text] [Related]
13. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study.
Shah AY; Karam JA; Malouf GG; Rao P; Lim ZD; Jonasch E; Xiao L; Gao J; Vaishampayan UN; Heng DY; Plimack ER; Guancial EA; Fung C; Lowas SR; Tamboli P; Sircar K; Matin SF; Kimryn Rathmell W; Wood CG; Tannir NM
BJU Int; 2017 Dec; 120(6):782-792. PubMed ID: 27860149
[TBL] [Abstract][Full Text] [Related]
14. Haplotype-resolved germline and somatic alterations in renal medullary carcinomas.
Tan KT; Kim H; Carrot-Zhang J; Zhang Y; Kim WJ; Kugener G; Wala JA; Howard TP; Chi YY; Beroukhim R; Li H; Ha G; Alper SL; Perlman EJ; Mullen EA; Hahn WC; Meyerson M; Hong AL
Genome Med; 2021 Jul; 13(1):114. PubMed ID: 34261517
[TBL] [Abstract][Full Text] [Related]
15. Renal medullary carcinoma involving serous cavity fluids: a cytomorphologic study of 12 cases.
Miller DL; Ribeiro EA; Roy-Chowdhuri S; Illei PB; Siddiqui MT; Ali SZ
J Am Soc Cytopathol; 2021; 10(2):187-196. PubMed ID: 32651128
[TBL] [Abstract][Full Text] [Related]
16. Renal Cell Carcinoma, Unclassified with Medullary Phenotype and Synchronous Renal Clear Cell Carcinoma Present in a Patient with No Sickle Cell Trait/Disease: Diagnostic and Therapeutic Challenges.
Lai JZ; Lai HH; Cao D
Anticancer Res; 2018 Jun; 38(6):3757-3761. PubMed ID: 29848739
[TBL] [Abstract][Full Text] [Related]
17. Renal medullary carcinoma: A national analysis of 159 patients.
Ezekian B; Englum B; Gilmore BF; Nag UP; Kim J; Leraas HJ; Routh JC; Rice HE; Tracy ET
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28485059
[TBL] [Abstract][Full Text] [Related]
18. Renal medullary carcinoma: the Bronx experience.
Hakimi AA; Koi PT; Milhoua PM; Blitman NM; Li M; Hugec V; Dutcher JP; Ghavamian R
Urology; 2007 Nov; 70(5):878-82. PubMed ID: 18068443
[TBL] [Abstract][Full Text] [Related]
19. Novel renal medullary carcinoma cell lines, UOK353 and UOK360, provide preclinical tools to identify new therapeutic treatments.
Wei D; Yang Y; Ricketts CJ; Vocke CD; Ball MW; Sourbier C; Wangsa D; Wangsa D; Guha R; Zhang X; Wilson K; Chen L; Meltzer PS; Ried T; Thomas CJ; Merino MJ; Linehan WM
Genes Chromosomes Cancer; 2020 Aug; 59(8):472-483. PubMed ID: 32259323
[TBL] [Abstract][Full Text] [Related]
20. Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary Carcinomas.
Calderaro J; Masliah-Planchon J; Richer W; Maillot L; Maille P; Mansuy L; Bastien C; de la Taille A; Boussion H; Charpy C; Jourdain A; Bléchet C; Pierron G; Gentien D; Choudat L; Tournigand C; Delattre O; Allory Y; Bourdeaut F
Eur Urol; 2016 Jun; 69(6):1055-61. PubMed ID: 26433572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
